For information on this past event please contact Meetings Management

POSTER SESSION

Poster 101
‘Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA+ IL-12DNA) against tuberculosis using the cynomolgus monkey model of TB’
Masaji Okada et al. (Kinki-Chuo Chest Medical Center, Osaka, Japan)

Poster 102
‘Development of an interim working reference for intracellular flow cytometry for use in TB vaccine trials studies’
D. Bryan et al. (NIBSC, Potters Bar, UK)

Poster 103
‘The Cotton Rat (Sigmodon hispidus) model of pulmonary tuberculosis’
Christine McFarland et al. (Texas A&M Health Science Center, College Station, Texas, USA)

Poster 104
‘Vaccination in wild boar (Sus scrofa)’
L. de Juan et al. (Faculty of Veterinary Sciences, Madrid, Spain)

Poster 105
‘The epidemiology of TB in adolescents as a basis for TB vaccine trials’
H. Mahomed et al. (University of Cape Town, South Africa)

Poster 106
‘Phase III TB vaccine trial site networking’
A.H. van’t Hoog et al. (KEMRI/CDC Program, Kisumu, Kenya)

Poster 107
‘Results of a phase I study evaluating the safety and immunogenicity of a new TB vaccine, MVA85A, in healthy adolescent volunteers with no evidence of infection with Mycobacterium tuberculosis’
M. Tameris et al. (SATVI, Worcester, South Africa)

Poster 108
‘Perceptions of novel TB vaccines and willingness to participate in TB vaccine trials in Nigeria’
O. Onigbogi (University College Hospital, Ibadan, Nigeria)

Poster 109
‘Development and application of immunological reagents to the study of vaccine-induced resistance to tuberculosis in guinea pigs’
A. Jeevan et al. (Texas A&M HSC, College Station, Texas, USA)

Poster 110
‘Mining the Mycobacterium tuberculosis proteome: Why haven’t we found what we are looking for?’
Karen M. Dobos et al. (Colorado State University, Fort Collins, Colorado, USA)

Poster 111
‘Immunogenicity and protection of prime-boost regimens using TB vaccine candidates in nonhuman primates’
Charles A. Scanga et al. (Aeras Global TB Vaccine Foundation, Rockville, Maryland, USA)

Poster 112
‘Role of the antimicrobial peptide hepcidin in the innate immune response to Mycobacterium tuberculosis’
F.B. Sow et al. (Centers for Disease Control and Prevention, Atlanta, USA)

Poster 113
‘Novel antimycobacterial agents targeting mycolate synthesis: Are they pyrazinamide like?’
Amani Alnimr et al. (University College Medical School, London, UK)

Poster 114
‘Identification of the core immunogenic region of PPE68 identical between pathogenic Mycobacterium tuberculosis and the vaccine strains of M. bovis BCG’
A.S. Mustafa et al. (Kuwait University, Kuwait)

Poster 115
‘A follow up study of clinical and histopathological evaluation of the immunotherapeutic effect of Mycobacterium w (Mw) vaccine in borderline leprosy’
Raj Kamal et al. (Jalma Institute, Agra, India)

Poster 116
‘Development of an aerosol model of pulmonary tuberculosis in the rhesus macaque’
Chad J. Roy et al. (Tulane National Primate Research Center, Covington, USA)

Poster 117
‘Protective activity of two subpopulations from Bacillus Calmette-Guerin (BCG) Japanese substrain with different RD16 regions’
S. Yamamoto et al. (Texas A&M University, College Station, Texas, USA)

Poster 118
‘An efficient tool for the construction of multiantigenic – DNA vaccine candidates and its proof-of-concept application against Mycobacterium tuberculosis’
Fayaz-Ahmad Mir et al. (Max-Planck-Institute for Infection Biology, Berlin, Germany)

Poster 119
‘Novel recombinant BCG vaccine with combined endosome escape and antigen over-expression properties: pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis’
Yasir A.W. Skeiky et al. (Aeras Global TB Vaccine Foundation, Rockville, Maryland, USA)

Poster 120
‘Mutant Escherchia coli enterotoxin as a mucosal adjuvant induces specific Th1 responses of CD4+ and CD8+ T cells to nasal killed-Bacillus Calmette-Guerin in mice’
T. Tsuji et al. (Fujita Health University, Aichi, Japan)

Poster 121
‘Comparison of tuberculin skin testing with a whole-blood interferon gamma assay (QuantiFERON TB Gold) and ELISA serologic assay, for diagnostic of tuberculosis in HIV positive adolescents’
H. Stavri et al. (National Research Institute for Microbiology & Immunology, Bucharest, Romania)

Poster 122
‘Patient derived M. tuberculosis Beijing strains translocate from the phagolysome to cytosol’
N. van der Wel et al. (The Netherlands Cancer Institute, Amsterdam, The Netherlands)

Poster 123
‘Building staff capacity for clinical research in developing countries’
J. Neibert et al. (Aeras Global TB Vaccine Foundation, Rockville, Maryland, USA)

Poster 124
‘IC31: a novel adjuvant that potently activates Type I immune responses’
K. Lingnau et al. (Intercell AG, Vienna, Austria)

Poster 125
‘Effect of extend freeze-drying BCG on TLR-2 and NADPH components expression, and cytokine production on human leucocytes’
J. Moreira et al. (University of Sao Paulo, Brazil)

Poster 126
‘Preparing for tuberculosis vaccine trials in a rural/peri-urban community setting in Uganda: Opportunities, challenges and lesson thus far’
A. Wajja et al. (Makerere University, Uganda)

Poster 127
‘A comparative study of host cell responses to M._tuberculosis PE_PGRS proteins’
P.P. Singh et al. (CBER, FDA, Bethesda, Maryland, USA)

Poster 128
‘Therapeutic use of infliximab to control severe paradoxical reaction in a patient with disseminated tuberculosis involving the lung, brain and lymph nodes’
R. Wallis et al. (PPD, Washington DC, USA)

Poster 129
‘Suitability of a recent clinical isolate of M. tuberculosis as an indicator of adaptive mycobacterial immunity following natural infection, using whole blood culture’
R. Wallis et al. (PPD, Washington DC, USA)

Poster 130
‘Characterization of the effectiveness of new recombinant Modified Vaccinia Ankara vaccines against tuberculosis’
K. Kolibab et al. (CBER, FDA, Bethesda, Maryland, USA)

Poster 131
‘Construction and evaluation of a stable recombinant BCG AERAS-407 using protein antigens identified by a whole genome analysis’
K. Velmurugan et al. (Aeras Global TB Vaccine Foundation, Rockville, Maryland, USA)

Poster 132
‘Evaluating old and new TB vaccines: The search for correlates of protection and a new potency assay’
M. Parra et al. (CBER, FDA, Bethesda, Maryland, USA)

Poster 133
‘Cryo-preserved whole blood for use in cell mediated immunity (CMI) assays’
S. Goldberg et al. (Aeras Global TB Vaccine Foundation, Rockville, Maryland, USA)

Poster 134
‘Quantification (CFU determination) and live/dead discrimination of BCG by flow cytometry’
S. Mueller et al. (Aeras Global TB Vaccine Foundation, Rockville, Maryland, USA)

Poster 135
‘Assessment of Ag85B specific T-cells in PPD+ individuals using tetramer technology’
J. Gearhart et al. (Aeras Global TB Vaccine Foundation, Rockville, Maryland, USA)

Poster 136
‘Bacterially delivered dsRNA vaccine elicits enhanced immune responses when compared with Ad35 and rBCG vaccines’
R. Anantha et al. (Aeras Global TB Vaccine Foundation, Rockville, Maryland, USA)

Poster 137
‘Evaluating the persistence of a new rBCG vaccine candidate, AERAS-406, in the mouse model’
Khairul-Bariah Abdul-Majid et al. (Aeras Global TB Vaccine Foundation, Rockville, Maryland, USA)

Poster 138
‘Effect of delaying BCG vaccination of infants to 14 weeks on the specific T cell response’
B. Kagina et al. (SATVI, University of Cape Town, South Africa)

Poster 139
‘Report of an international collaborative study to establish the suitability of using modified ATP assay for viable count of BCG vaccine’
K. Markey et al. (NIBSC, Potters Bar, UK)

Poster 140
‘Whole blood assay to assess altered cytokine secretion in tuberculosis patients with poorly controlled type 2 diabetes’
B.I. Restrepo et al. (University of Texas, Houston, Texas, USA)

Poster 141
‘CD8 T-cells: Function and correlation with bacterial virulence under murine infection with M. tuberculosis’
R. Billeskov et al. (Statens Serum Institut, Copenhagen, Denmark)

Poster 142
‘The effect of anti-tuberculosis T cell immunity following vaccination with recombinant antigens’
T. Elvang et al. (Statens Serum Institut, Copenhagen, Denmark)

Poster 143
‘The pathology of MDR strains of Mycobacterium tuberculosis as targets for new vaccine testing’
G.S. Palanisamy et al. (Colorado State University, Fort Collins, Colorado, USA)

Poster 144
‘Post-exposure vaccination against Mycobacterium tuberculosis’
G.S. Palanisamy et al. (Colorado State University, Fort Collins, Colorado, USA)

Poster 145
‘The effect of BCG vaccination on the expression of host immunity in the lungs of guinea pigs infected with Mycobacterium tuberculosis’
I.M. Orme et al. (Colorado State University, Fort Collins, Colorado, USA)

Poster 146
‘Development of immunogenic chimeric and fusion proteins against Mycobacterium tuberculosis’
A. Ghaffar et al. (NIBGE, Faisalabad, Punjab, Pakistan)

Poster 147
‘Novel nasal booster vaccines against tuberculosis’
A. Pawlowski et al. (Swedish Institute for Infectious Disease Control, Stockholm, Sweden)

Poster 148
‘IL-12N220L DNA vaccine augments protective effects of the BCG vaccine against M. tuberculosis infection in the mice’
Bo-Young Jeon et al. (Yonsei University College of Medicine, Seoul, Korea)

Poster 149
‘Investigation of potential biomarkers in BCG vaccinated rhesus macaques protected from aerosol challenge with M. tuberculosis’
S. Sharpe et al. (Health Protection Agency, Porton Down, Salisbury, UK)

Poster 150
‘Towards a prospective epidemiological study and site development for phase III tuberculosis vaccine studies among infants and adolescents in Uganda’
H. Mayanja-Kizza et al. (Makarere University, Kampala, Uganda)

Poster 151
‘Dendritic cell targeting in the design of tuberculosis vaccines’
W. Sun et al. (National University of Singapore, Singapore)

Poster 152
‘Natural history of virulent Mycobacterium tuberculosis Erdman strain infection in rhesus monkeys’
Ana Cristina Leandro et al. (Southwest Foundation for Biomedical Research, San Antonio, Texas, USA)

Poster 153
‘A single dose of prime-booster DNA-hsp65 and DNA-encoding antigen TDM-loaded microspheres vaccine elicited both CD4 and CD8 activated T cells in non-human primate model’
Ana Cristina Leandro et al. (Southwest Foundation for Biomedical Research, San Antonio, Texas, USA)

Poster 154
‘Should antituberculosis vaccination studies consider the lung compartment?’
S.K. Schwander and M. Torres (University of Medicine and Dentistry, New Jersey, USA)

Poster 155
‘Inactivation of CD4+CD25+ T regulatory cells prior to BCG vaccination accelerates secondary immune responses but does not enhance protection against tuberculosis’
J.R. Kirman et al. (Malaghan Institute of Medical Research, Wellington, New Zealand)

Poster 156
‘Using mRNA expression profiling to elucidate BCG-induced biomarkers of protection against childhood tuberculosis disease’
H. Fletcher et al. (Jenner Institute, University of Oxford, UK)